World Market for Oncology Imaging AI

Description

List of Tables

Oncology is where medical imaging AI is being tested most aggressively-and where it is starting to stick. Breast and lung screening programs, complex CT/MRI staging, PET-based theranostics, and RT planning are all pushing clinicians toward faster, more consistent, more quantitative imaging decisions.

This Markintel(TM) Horizon report quantifies and explains that shift. It analyzes the World Market for Oncology Imaging AI from 2023 to 2032, using a consistent segmentation across:

Modality: CT, X-ray/DR (incl. DBT), MRI, PET/Nuclear, Ultrasound
Tumor site: Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-oncology, and others
Clinical application & pathway stage: from Screening & Risk through Treatment Planning and Response
Revenue stream & buyer type: Hardware attach, Software, Services, Cloud/PPU across Cancer Centers, IDNs/AMCs, Community providers, and Teleradiology

Beyond the numbers, the report applies the full Markintel framework stack-M3, ARC-Index, GTM Growth-Maturity, and the new Upgrade & Package Ladders-to show how AI Software vendors, Imaging OEMs, RT planning providers, AI Platforms, Providers/Telerad networks, and Imaging-Pharma/CROs can convert opportunity into repeatable, profitable business.

The goal is not just to describe the market, but to give executives an insights-to-action playbook: where Oncology Imaging AI is truly ready to scale, which clusters will capture the value, and what evidence, packaging, and partnerships will matter most over the next three to five years.

Market Snapshot

Oncology Imaging AI has moved from experimental pilots to a fast scaling market. The report sizes a global opportunity that expands more than 10x between 2023 and 2032, with a compound annual growth rate in the low 30s. North America remains the largest revenue pool over the horizon, but Asia-Pacific is the fastest growing region, overtaking Europe on momentum as national breast and lung programs, domestic OEMs, and cloud first deployments ramp. Europe stays a strong second engine, with adoption paced by MDR, HTA, and national screening strategies.

Most spend concentrates in CT, X ray/DBT and MRI oncology workflows, with PET/Nuclear and Ultrasound forming smaller but high value niches tied to theranostics, quantification, and interventional oncology. The mix of value pools also shifts along the pathway: Detection & Diagnosis remains foundational, but more spend migrates toward screening, treatment planning, and response assessment, where lesion level segmentation, dosimetry, and structured reporting are becoming mandatory for modern cancer programs.

The report quantifies Oncology Imaging AI across regions and countries, modalities, tumor sites, clinical applications, pathway stages, revenue streams, and end use settings (cancer centers, IDNs/AMCs, community providers, teleradiology). Detailed numbers are reserved for report buyers; the public snapshot is directional by design.

What's Covered:

Global market sizing & forecast (2023-2032) - total Oncology Imaging AI market today and through 2032, with growth outlook, scenario commentary and key inflection points along the decade.
Granular segmentation of value pools - analysis by modality, tumor site, clinical application, pathway stage, revenue stream and end-use setting (cancer centers, IDNs/AMCs, community hospitals, imaging centers, teleradiology), aligned with the broader Markintel(TM) AI-in-Imaging taxonomy.
Regional & country perspectives - detailed views for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, including commentary on leading and fast-growth countries, screening initiatives, and local regulatory/reimbursement dynamics.
Clinical & technology trends across the oncology pathway - how AI is being deployed from breast and lung screening through CT/MR staging, RT planning, PET theranostics and longitudinal response assessment, with use-case mapping to Screening, Diagnosis, Staging, Planning, Response and Surveillance stages.
Regulatory, reimbursement and evidence landscape (ARC) - assessment of Approvals, Reimbursement and Clinical validation by key use case (e.g., DBT AI, CT-lung, adaptive RT, PET response, radiomics), including where Oncology Imaging AI is deployment-ready vs where it remains pilot-only.
Competitive landscape by cluster - analysis of six major competitive clusters (AI Software, Imaging OEMs, RT/TPS vendors, AI Platforms & Cloud, Providers & Teleradiology, Imaging-Pharma/CRO & Trials), with GTM Growth-Maturity positioning and qualitative company spotlights.
GTM & packaging strategies - Markintel Upgrade & Package Ladders for each cluster (Foundation / Advanced / Elite), recommended commercial and pricing rules, channel and partnership strategies, and implications for attach-rate expansion and suite-based selling.
Strategic implications & scenarios - cross-cutting insights on where Oncology Imaging AI is likely to become "workflow-critical infrastructure," how APAC's faster growth changes global competition, and what boards, product leaders and investors should prioritize over the next 3-5 years.

Companies Covered:

5C Network
Accuray
Aidoc
AIQ Solutions
Bracco
Brainlab
Canon Medical
CARPL.ai
deepc (deepcOS)
DocPanel
Elekta
Everlight Radiology
Ferrum Health
Fujifilm Healthcare
GE HealthCare
Guerbet
Hologic
Incepto
Koios Medical
Lantheus / EXINI (aPROMISE / PYLARIFY AI)
Limbus AI
Lunit

Median Technologies
MIM Software
Mirada Medical
MVision AI
Nuance Precision Imaging Network (PIN)
Philips Healthcare
Quibim
QView Medical
RadNet / DeepHealth
RaySearch Laboratories
Riverain Technologies
Samsung Healthcare
ScreenPoint Medical (Transpara)
Siemens Healthineers
Teleradiology Solutions
Tempus (Arterys)
Therapixel (MammoScreen)
Unilabs / Telemedicine Clinic (TMC)
United Imaging
Vara
vRad

The list is cluster balanced-it includes AI software specialists, modality OEMs, RT/TPS vendors, platform players, provider/telerad networks, and imaging pharma/iCROs that feature in the oncology analysis.

KEY STATISTICS
Geographical Coverage:	North America (US, Canada) Europe (Germany, France, UK, Italy, Rest of Europe) Asia Pacific (China, Japan, India, Rest of Asia-Pacific) Latin America Middle East & Africa
Market Segmentation:	By Modality (CT, X-ray/DR. MRI, PET/Nuclear, Ultrasound) By Geographic Region (see above for Geographic Coverage) By Tumor Site (Breast, Lung/Chest, Prostate, Colorectal, Liver, Neuro-Onc, Gyn, H&N, Other) By Clinical Application (Detection/Triage, Seg/Quant, Reporting/NLP, Recon/Dose, Workflow Orchestration) By Pathway Stage (Screening, Diagnosis, Staging, Planning (RT), Therapy Response, Surveillance) By End-Use Org (Cancer Centers, IDNs/AMCs, Community Hospitals, Imaging Centers, Teleradiology) By Revenue Stream (Hardware Uplift, Software Licenses, Services, Cloud/PPU) By AI Technology (Detection, Seg/Quant, Radiomics, NLP/LLM, Governance)
Key Topics Covered:	Global market sizing & forecast (2023-2032) Granular segmentation of value pools Regional & country perspectives Clinical & technology trends across the oncology pathway Regulatory, reimbursement and evidence landscape (ARC) Competitive landscape by cluster GTM & packaging strategies Strategic implications & scenarios
Methodology:	Markintel Horizon Research Program - Medical Imaging & AI

Product Code: MINTH-M01119

SECTION 1 - EXECUTIVE SUMMARY

Why This Market Matters - The 25-Second Read

Global Growth at A Glance (2023-2032)

Where Along the Pathway the Money Is Moving

Global Market Drivers & Restraints

Key Growth Drivers
Structural Restraints

Regional Pulse - Who Leads, Who Accelerates

North America
Asia-Pacific
Europe
LATAM & MEA

Five Strategy Headlines to Internalize

Structural Shifts by Modality, Application, Pathway, And End-Use

Competitive Architecture and Vendor Clusters

Three-Year KPI Outlook (2025-2027) & Board-Level Actions

Three-Year KPI Outlook
Actions For Vendors Over the Next 12 Months

SECTION 2 - RESEARCH METHODOLOGY

About This Report

Scope & Segmentation - What is Being Measured

Segmentation Axes

Dual-Lens Architecture - How Numbers Are Built

Top-Down Market Funnel - Anchoring the Oncology Slice

Bottom-Up Attach-Rate Flow - How Oncology Revenue Actually Accrues

Evidence Confidence - How We Weight and Quality-Check Inputs

Framework Stack - Why the Numbers Are Actionable

Company Coverage, GTM Growth-Maturity & Competitive Datasets

Company Universe And Clustering
GTM Growth-Maturity Quadrants
Competitive Dataset Tables
Evidence Confidence

Upgrade & Package Ladders

Definition
Default Commercial Rules

Cluster-Based Competitive Architecture & Market Segment Bridging

Clusters (Roles)
Global Cluster<->Segment Bridge

Quality Assurance, Limitations, And Scenario Handling

SECTION 3 - STRATEGIC ANALYSIS & FRAMEWORKS

AI SOFTWARE CLUSTER

Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
- How to Read This Matrix
Markintel ARC Framework - Oncology Use Cases Addressable by AI Software Lens
- Markintel ARC Grid - AI Software (Oncology Imaging AI)
- How to Read This Exhibit
- ARC-Index by Segment - AI Software (Oncology Imaging AI)
- ARC -> Upgrade Ladder Mapping - AI Software
- Recommendations (AI Software Vendors)
Markintel GTM Growth-Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
- How To Read This Matrix
- Competitive Dataset - AI Software - Oncology Imaging AI
- Company Scoreboard - AI Software - Oncology Imaging AI
- AI Software - Market Segmentation Bridge
Markintel Upgrade & Package Ladder - AI Software (Oncology Imaging AI)
- Objective
- Upgrade Ladder Structure - AI Software (Oncology) Packages
- Target Customers & Package Composition - AI Software - Oncology Upgrade & Package Ladder
- Recommended Commercial Rules - AI Software (Oncology)
Company Spotlights - AI Software Cluster
- Aidoc
- AIQ Solutions
- Koios Medical
- Lunit
- Median Technologies
- Quibim
- QView Medical
- RadNet / DeepHealth
- Riverain Technologies
- ScreenPoint Medical (Transpara)
- Therapixel (MammoScreen)
- Vara

IMAGING OEMs CLUSTER (ONCOLOGY ATTACH & AI SUITES)

Markintel M3 - Market Momentum Matrix (Imaging OEMs Key Sub-Segments)
- How to Read This Matrix
Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by OEMs
- Key OEM Oncology Segments
- ARC Grid - Imaging OEMs
- How to Read This Exhibit
- ARC Table - Imaging OEMs (Oncology)
Markintel GTM Growth-Maturity Matrix - Imaging OEMs (Oncology Imaging AI)
- Competitive Dataset - Imaging OEMS - Oncology Imaging AI
- How to Read this Matrix
- Imaging OEMs Competitive Scoreboard - Oncology Imaging AI
- Imaging OEMs Cluster - Oncology Imaging AI Market Segmentation Bridge
Upgrade & Package Ladder - Imaging OEMs Lens (Oncology Imaging AI)
- Objective
- Ladder Structure - OEM Oncology Packages
- Imaging OEMs - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
- Recommended Commercial Rules - OEM Oncology Cluster
Company Spotlights - Imaging OEMs (Oncology Attach & AI Suites)
- Canon Medical
- Fujifilm Healthcare
- GE HealthCare
- Hologic
- Philips Healthcare
- Samsung Healthcare
- Siemens Healthineers
- United Imaging

RT / ONCOLOGY PLANNING CLUSTER (AUTO-CONTOUR, ADAPTIVE, DOSE/RESPONSE)

Executive Summary
Markintel M3 - Market Momentum Matrix of Key Subsegments (RT/Oncology Planning Lens)
- What it Says (RT / Oncology Planning)
Markintel ARC-Framework by Oncology Use Case (RT/Oncology Planning Lens)
- ARC Grid - RT/Oncology Planning
- ARC Table - RT / Oncology Planning
- RT Recommendations
Markintel GTM Growth-Maturity Matrix -- RT & Oncology Planning Vendors (Oncology Imaging AI)
- Competitor Scoreboard
- RT / Oncology Planning - Market Segmentation Bridge
Markintel Upgrade & Package Ladder - RT / Oncology Planning
- Objective
- Ladder structure - RT / Oncology Planning packages
- RT/Oncology Planning Cluster - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
- Recommended Commercial Rules - RT / Oncology Planning
Company Spotlights - RT / Oncology Planning
- Accuray
- Brainlab
- Elekta
- Limbus AI
- MIM Software
- Mirada Medical
- MVision AI
- RaySearch Laboratories
- Varian (Siemens)

AI PLATFORMS & CLOUD CLUSTER (NEUTRAL PLATFORMS, ORCHESTRATION, MARKETPLACES)

Executive Summary
Markintel M3 - Market Momentum Matrix (AI Platforms & Cloud Key Sub-Segments)
- What it Says (AI Platforms & Cloud)
Markintel ARC Framework - Oncology Use Cases Addressable by AI Platforms & Cloud
- ARC Grid - AI Platforms & Cloud
- ARC Table - AI Platforms & Cloud
Markintel GTM Growth-Maturity Matrix - AI Platforms & Cloud Providers (Oncology Imaging AI)
- Competitor Scoreboard
- AI Platforms & Cloud - Market Segmentation Bridge
Upgrade & Package Ladder - AI Platforms & Cloud (Oncology)
- Objective
- Ladder Structure - Platform & Cloud packages
- AI Platforms & Cloud - Oncology Upgrade & Package Ladder - Oncology Imaging AI
- Recommended Default commercial Rules - Platforms & Cloud
Company Spotlights - AI Platforms & Cloud
- CARPL.ai
- deepc (deepcOS)
- Ferrum Health
- Incepto
- Nuance Precision Imaging Network (PIN)
- Tempus (Arterys)

PROVIDERS & TELERADIOLOGY CLUSTER (AI-ASSISTED SERVICES)

Executive Summary
Markintel M3 - Market Momentum Matrix (Providers & Teleradiology Key Subsegments)
- What it Says (Providers & Telerad)
Markintel ARC Framework - Oncology Use Cases Addressable by Providers & Teleradiology
- ARC Grid - Providers & Teleradiology
- ARC Table - Providers & Teleradiology
GTM Growth-Maturity Matrix - Providers & Teleradiology Networks (Oncology Imaging AI)
- Competitive Dataset - Services Rails, Governance, Oncology Footprint
- Competitive Scoreboard
- Providers & Teleradiology - Market Segmentation Bridge
Markintel Upgrade & Package Ladder - Providers & Teleradiology (Oncology)
- Objective
- Ladder Structure - Oncology Service Packages
- Providers & Teleradiology - Oncology Upgrade & Package Ladder - Target Customers & Package Composition
- Recommended Default Commercial Rules - Providers & Teleradiology
Company Spotlights - Providers & Teleradiology (AI-Assisted Services)
- 5C Network
- Everlight Radiology
- DocPanel
- RadNet / DeepHealth
- Teleradiology Solutions
- Unilabs / Telemedicine Clinic (TMC)
- vRad

IMAGING-PHARMA / CRO & TRIALS CLUSTER (RADIOMICS, RESPONSE, THERANOSTICS)

Executive Summary
Markintel M3 - Market Momentum Matrix (Imaging-Pharma / CRO & Trials Key Sub-Segments)
- M3 Table - Imaging-Pharma / CRO & Trials
Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by Imaging-Pharma / CRO & Trials
- ARC Grid - Imaging-Pharma / CRO & Trials
- ARC Table - Imaging-Pharma / CRO & Trials
Markintel GTM Growth-Maturity Matrix - Imaging-Pharma & CROs (Oncology Imaging AI)
- Competitive Dataset - endpoint standardization & clinic bridge
- Competitor Scoreboard
- Imaging-Pharma / CRO & Trials - Market Segmentation Bridge
Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials
- Objective
- Ladder Structure - Imaging-Pharma / CRO & Trials
- Imaging-Pharma / CRO & Trials - Upgrade & Package Ladder - Target Customers and Package Composition
- Recommended Default Commercial Rules - Imaging-Pharma / CRO & Trials
Company Spotlights - Imaging-Pharma / CRO & Trials (Radiomics, Response, Theranostics)
- AIQ Solutions
- Bracco
- Guerbet
- Lantheus / EXINI (aPROMISE / PYLARIFY AI)
- Median Technologies
- Quibim

SECTION 4 - WORLD MARKET FOR ONCOLOGY IMAGING AI

WORLD MARKET OVERVIEW

Oncology Imaging AI: From Niche App to Enterprise Platform
- Why Adoption is Accelerating
Regional Growth Snapshot (2023 -> 2032)
Strategic Implications for Vendors
Market Momentum & Outlook

WORLD MARKET FORECAST BY REGION (2023-2032)

WORLD MARKET BY COUNTRY x END-USE ORG

Estimate by Country x End-Use (USD Mill, 2023)
Forecast by Country x End-Use (2032)
Highlights (2032 Country Pattern vs World Mix)
What's Shifting vs 2023 (Directional)
Top Growth Cells (US$ M Lift, 2023->2032)
What This Means (Commercial Playbook)
Signals to Watch

WORLD MARKET BY MODALITY

Highlights
World Market by Modality (2023-32)
- Implications
Market Math & Diffusion Pattern
- 2032 Mix and Key Growth Lenses
- Share Shift and Dollar Lift (2023 -> 2032)
Competitive Landscape - by Modality
Modality Deep-Dives (Oncology-specific)
- CT
- X-ray/DR (incl. Mammography)
- MRI
- PET/Nuclear
- Ultrasound
Strategic Takeaways for Vendors (Oncology-specific)
Signals to Watch (2025-2027)

WORLD MARKET BY CLINICAL APPLICATION

Highlights
World Market by Clinical Application (2023-32)
What's Shifting
Key Growth Lenses by Application
Who Contributes the Growth (2023->2032 lift)
What This Means
Competitive Landscape - by Clinical Application
Deep Dives by Clinical Application
- Detection & Diagnosis
- Quantification & Analytics
- Workflow & Orchestration
- Reporting & Communication
- Image Reconstruction & Acquisition
Strategic Takeaways for Vendors
Signals to Watch (2025-2027)

WORLD MARKET BY TUMOR SITE

Highlights
What's Shifting (Mix Dynamics)
World Market by Tumor Site (2023-32)
Growth Lenses - by Tumor Site
What This Means
What Shifts Through 2032
Commercial Takeaways
Competitive Landscape - by Tumor Site
Deep Dives by Tumor Site
- Breast
- Lung/Chest
- Prostate
- Colorectal
- Liver
- Neuro-Oncology
- Gynecologic
- Head & Neck
- Other (Rare)
Strategic Takeaways
Signals to Watch (2025-2027)

WORLD MARKET BY REVENUE STREAM

Highlights
What's Shifting
World Market by Revenue Stream (2023-32)
Growth Lenses - by Revenue Stream
Who Contributes the Growth (2023->2032 Dollar Lift)
What This Means
Deep Dives by Revenue Stream
- Hardware
- Software
- Service
- Cloud/PPU
Competitive Landscape - by Revenue Stream
Signals to Watch (2025-2027)

WORLD MARKET BY END-USE ORGANIZATION TYPE

Highlights
What's Shifting
World Market by End-Use Organization (2023-32)
Growth Lenses by End-use
Who Contributes the Growth (2023->2032 Dollar Lift)
What this Means
Deep Dives
- Academic/IDNs
- Comprehensive Cancer Centers
- Community Hospitals & Imaging Centers
- Teleradiology Providers
Competitive Landscape - by End-Use
Signals to Watch (2025-2027)

WORLD MARKET BY AI TECHNOLOGY

Highlights
What's Shifting
World Market by AI Technology (2023-32)
Growth Lenses - by AI Technology
Who Contributes the Growth (2023->2032 Dollar Lift)
What This Means
Deep Dives by AI Technology (Oncology Lens)
Competitive Landscape - by AI Technology
Signals to Watch (2025-2027)

WORLD MARKET BY PATHWAY STAGE

Highlights
What's Shifting
World Market by Pathway Stage (2023-32)
Growth Lenses - by Pathway Stage
Who Contributes the Growth (2023->2032 Dollar Lift)
What This Means
Competitive Landscape - by Pathway Stage
Signals to Watch (2025-2027)

REGIONAL MIX & MOMENTUM - WORLD ONCOLOGY IMAGING AI

Executive Takeaways
Marke by Region x Modality
- World Market by Region x Modality - 2023
- World Market by Region x Modality - 2032
- What's Shifting (Mix, 2032 Over/Under-index)
- Who Contributes the Growth (2023->2032 Lift)
- What This Means
Market by Region x Revenue Stream
- World Market by Region x Revenue Stream - 2023
- World Market by Region x Revenue Stream - 2032
- What's Shifting (Mix, 2032 Over/Under Index)
- Who Contributes the Growth
- What This Means
Market by Region x Clinical Application
- World Market by Region x Clinical Application - 2023
- World Market by Region x Clinical Application - 2032
- What's Shifting (Mix, 2032 Over/Under Index)
- Who Contributes the Growth
- What this Means
- Competitive Snapshots (Illustrative)

DISEASE-DRIVEN DEMAND MAP - WORLD ONCOLOGY IMAGING AI

Executive Takeaways
Tumor Site x Modality
- World Market by Tumor Site x Modality - 2023
- World Market by Tumor Site x Modality - 2032
- What's Shifting (2032 Mix vs Global)
- Who Contributes the Growth (2023->2032 Dollar Lift)
- What This Means
Tumor Site x Clinical Application
- World Market by Tumor Site x Clinical Application - 2023
- What's Shifting (2032 Mix vs Global)
- World Market by Tumor Site x Clinical Application - 2032
- Who Contributes the Growth (2023->2032 Dollar Lift)
- What this means
Tumor Site x Revenue Stream
- World Market by Tumor Site x Revenue Stream - 2023
- World Market by Tumor Site x Revenue Stream - 2032
- What's Shifting (2032 mix vs global)
- Who Contributes the Growth (2023->2032 Dollar lift)
- What This Means
Competitive Snapshot (Illustrative, Oncology-focused)
Signals to Watch

WORKFLOW ECONOMICS - WORLD ONCOLOGY IMAGING AI

Modality x Revenue Stream
- World Market by Modality x Revenue Stream - 2023
- World Market by Modality x Revenue Stream - 20232
- Highlights
- What's Shifting (Mix & Over/Under-Index)
- Who Contributes the Growth (2023->2032 Dollar Lift)
- What This Means (Commercial Playbook)
- Competitive Lens (Illustrative)
Clinical Application x Revenue Stream
- Highlights (2032 Pattern)
- World Market by Clinical Application x Revenue Stream - 2023
- World Market by Clinical Application x Revenue Stream - 2032
- What's Shifting (2023 -> 2032)
- Who Contributes the Growth (US$ M lift, 2023->2032)
- What This Means (Commercial Playbook by Application)
- Competitive Lens (Indicative, Non-exhaustive)
- Pricing Archetypes That Clear Approvals (What Buyers Say "Yes" to)
- Signals to Watch
- Risks & Watchouts

PATHWAY STAGE ECONOMICS - WORLD ONCOLOGY IMAGING AI

Pathway Stage x Revenue Stream
- Highlights
- World Market by Pathway Stage x Revenue Stream - 2023
- World Market by Pathway Stage x Revenue Stream - 2032
- What's Shifting (Mix vs Global)
- Who Contributes the Growth (2023 -> 2032 Dollar Lift)
- What This Means (Commercial Playbook)
- Competitive Lens (Indicative)
- Signals to Watch
Pathway Stage x Modality - Where Each Stage Leans and Why
- World Market by Pathway Stage x Modality - 2023
- World Market by Pathway Stage x Modality - 2032
- Highlights (2032 Pattern vs World Mix)
- Where the Dollars Moved (2023 -> 2032)
- Stage-specific Readouts (2032 Shares Inside Each Stage)
- What This Means (Commercial Takeaways)
- Competitive Lens (Illustrative, not Exhaustive)
- Signals to Watch
Pathway Stage x Clinical Application - How Workloads Drive Spend
- World Market by Pathway Stage x Clinical Application - 2023
- World Market by Pathway Stage x Clinical Application - 2032
- Highlights (2032 Pattern vs World Mix)
- Where the Dollars Moved (2023 -> 2032)
- What This Means (Commercial Playbook)
- Competitive Lens (Indicative)
- Signals to Watch
Pathway Stage x End-use - Who Buys What, and Where Growth Concentrates
- World Context (2032 End-use Mix)
- World Market by Pathway Stage x End-use - 2023
- World Market by Pathway Stage x End-use - 2032
- Highlights (2032 Pattern vs Global Mix)
- Who Contributes the Growth (US$ M lift 2023->2032)
- What This Means (Commercial Playbook by Stage)
- Competitive Lens (Indicative, Non-exhaustive)
- Signals to Watch
Pathway Stage x AI Technology - How Capability Mix Shifts Across the Cancer Pathway
- World Tech Mix
- World Market for Pathway Stage x AI Technology - 2023
- World Market for Pathway Stage x AI Technology - 2032
- Highlights (2032 Pattern vs Global Mix)
- Where the Dollars Moved (2023 -> 2032)
- What This Means (Commercial Playbook)
- Competitive Lens (indicative)
- Signals to Watch

SECTION 5 - NORTH AMERICA

North America - Market Overview & Dynamics

North America - Executive Summary
Market Size - (Country Roll-up)
- What's Moving the Market
- Key Differences to Plan Around
- Structure of Spend by Revenue Stream (NA)
- End-Use Organizations (NA)
- AI Technology (NA)
- Pathway Stage (NA)
- Strategic Implications (North America)
- What to Watch (Leading Indicators)

Market Analysis & Estimates + Forecasts

North America - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- North America - Market Math & Diffusion (Modality)
- What's Driving North America (Shared Signals)
- Where the Growth Comes From
- Buyer & Hosting Posture
- Commercial Playbook (NA)
- What's Common Across NA (Region-Level Truths)
- Key Differences (U.S. vs Canada)
- Competitive Lens (Indicative, NA-relevant)
- Regulatory & Reimbursement Scenarios (What to Plan for)
- Commercial Playbook (NA)
- Signals to Watch (Leading Indicators)
- Risks & Mitigations
- 90-Day Action List
North America - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Market Math & Diffusion - North America, Clinical Application
- Headline Math
- What's Common Across the Region
- Where the U.S. and Canada Differ (and How to Win)
- Who Drives the Growth
- Pricing & Packaging
- Competitive Lens (indicative)
- Signals to Watch ('25-'28)
- Risk Notes
North America - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Growth Engines (What's Moving)
- What's Shifting (Mix and Posture)
- Buyer & Hosting Posture (Regional Commonalities vs. Differences)
- Who Drives the Growth (by Tumor)
- Pricing & Packaging
- Signals to Watch ('25-'28)
- Actionable Mix
- Risks
North America - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Headline Mix & Lift (US$M, 2023->2032)
- What's Driving Spend Patterns
- US vs Canada - Common Rails, Different Motions
- Regulatory & Reimbursement Cues
- Packaging & Pricing Posture
- GTM by Stream
North America - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Headlines
- Where the Dollars Land by 2032
- Country Split of the Lift ('23->'32)
- Implications for Go-to-Market
North America - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Headlines
- Where the Dollars Land by 2032 (Share / CAGR / Lift)
- Mix Shift (2023 -> 2032)
- Country Split of Dollar-lift ('23->'32)
- Implications for Go-to-Market
North America - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Headlines
- Where the Dollars Land by 2032 (Share / CAGR / Lift)
- Mix Shift (2023 -> 2032)
- Country Split of the Dollar-Lift ('23->'32)
- Implications for Go-to-Market

SECTION 6 - UNITED STATES

US Market Overview and Dynamics

Market Size Summary
What's Driving the U.S. (Demand & Supply)
Attach, Pricing & Adoption Posture
Distribution Rails & OEM Effects
Regulatory, Evidence & Reimbursement Posture (Practical)
Buyer & Hosting Posture (What U.S. Committees Expect)
Commercial Playbook (How to Win)
Risks & Watch-outs
U.S. Vendor & Channel Snapshot (indicative)
United States - At-a-Glance
- Key Numbers (2023->2032)
- Three Takeaways

US Market Estimates & Forecasts

US Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting (2025->2029)
- Market Math & Diffusion (United States, Modality)
- Who Drives the Lift
- Pricing & Packaging (How to Win)
- Competitive Lens (Indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-day Playbook (US)
US Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting (2025->2029)
- Who Drives the Growth ('23->'32 Dollar-lift)
- Market Math & Diffusion (United States, Clinical Application)
- Pricing & Packaging - How to Win
- Competitive Lens (Indicative)
- Signals to Watch ('25-'28)
- Risks
US Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- Incidence & Screening Context (Indicative, US)
- What's Shifting (2025->2029)
- Who Drives the Growth ('23->'32 dollar-lift)
- Market Math & Diffusion (United States, Tumor Site)
- Pricing & Packaging - How to Win
- Signals to Watch
US Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting (2025->2029)
- Who Drives the Growth ('23->'32 dollar-lift)
- Market Math & Diffusion (United States, Revenue Stream)
- Pricing & Packaging - How to Win
- Buyer & Hosting Posture (US Reality)
- Signals to Watch
- 90-day Playbook (Practical)
- Competitive Lens (Indicative)
US Market by End-Use Organization Type
- Forecast by End-Use Organization (USD Mill, 2023-32)
- Highlights
- What's Shifting (2025->2029)
- Who Drives the Growth ('23->'32 dollar-lift)
- Market Math & Diffusion (United States, End-Use Org)
- Pricing & Packaging - How to Win
- Buyer & Hosting Posture (US)
- Signals to Watch
- 90-day Playbook
US Market by AI Technology
- Forecast by AI Technology (2023-32)
- Highlights
- What's Shifting (2025->2029)
- Who Drives the Growth ('23->'32 dollar-lift)
- Pricing & Packaging - How to Win
- Market Math & Diffusion (United States, AI Technology)
- Buyer & Hosting Posture (US)
- Signals to Watch
- 90-day Playbook
US Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting (2025->2029)
- Market Math & Diffusion (United States, Pathway Stage)
- Who Drives the Growth ('23->'32 dollar-lift)
- Pricing & Packaging - How to Win
- Buyer & Hosting Posture
- Signals to Watch
- 90-day Playbook

SECTION 7 - CANADA

Market Overview & Dynamics (2023->2032)
- Where the Growth is
- What's Driving Canada
- Commercial
Canada - At a Glance
- Key Numbers
- 2032 Mix Snapshot (Steady State)
- Where the Dollars Come From ('23->'32 Lift)
- Three Takeaways
Buyer & Hosting Posture (Canada)
Incidence & Screening (Context Signals)
Policy & Reimbursement Signals (Canada-specific)
Provider Landscape Snapshot (indicative, oncology-heavy)
Packaging & Pricing Realities (Canada)
Evidence & Regulatory Notes (Canada-relevant)
Competitive Landscape (Indicative Clusters)

Canada - Market Estimates & Forecasts (Canada)

Canada - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (What's Doing the Lifting)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Competitive Lens (Indicative Clusters)
- Signals to Watch
- Risks & Watch-outs
Canada - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Canada, Clinical Application)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Packaging & Monetization Matrix (Canada)
- Competitive Lens (Indicative Clusters)
- Signals to Watch
- Risks & Watch-outs
Canada - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Canada, Tumor Site)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Packaging & Monetization Matrix (by Tumor, Canada)
- Competitive Lens (Indicative)
- Signals to Watch
- Risks & Watch-outs
Canada - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Canada, Revenue Stream)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Packaging & Monetization Guardrails (Canada)
- Competitive Lens (Indicative)
- Signals to Watch
- Risks & Watch-outs
Canada - Market by End-Use Organization Type (2023-32)
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Canada, End-Use Orgs)
- What This Means (Commercial Playbook)
- Packaging & Monetization Matrix - by Buyer Type (Canada)
- Signals to Watch
- Risks & Watch-outs
Canada - Market by AI Technology (2023-32)
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Canada, AI Technology)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Packaging & Monetization Matrix (Canada)
- Competitive Lens (Indicative)
- Signals to Watch
- Risks & Watch-outs
Canada - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Canada, Pathway Stages)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Packaging & Monetization Matrix (Canada)

SECTION 8 - EUROPE

Market Overview and Dynamics

Headlines (Scale & Slope)
What's Changing Around Access & Regulation
- Reimbursement, Funding & Procurement (Where Money Comes From)
- Clinical & Operational Proof Points (Confidence to Buy)
- How the Money Splits
- Buyer-side Patterns
- Risks & Watch-outs
- Go-to-Market Implications (Europe-wide)
- 12-month Operating Plan (Minimum Viable)

Market Estimates & Forecasts

Europe - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Headlines
- Where the Dollars Land by 2032 (Europe Totals; rounded)
- Source: Marketstrat Estimates & Forecast Model
- Country Split of the Lift ('23->'32)
- Growth vs. Scale (what the Bubble shows)
- Mix-shift (2023 -> 2032)
- Implications for Go-to-Market
Europe - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Europe Totals by Clinical Application
- Deeper Dive
- Who Drives Each Application? (2032 Revenue Split Within Each Application)
- Interpretation
- Commercial Implications
Europe - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- Europe Totals by Tumor Site (Rolled-Up; Rounded)
- Who Drives Each Site? (2032 revenue split within site)
- Commercial Implications
Europe - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Headlines
- Structure of Spend (rolled-up, rounded)
- What This Means
- Commercial Moves
Europe - Market by End-Use Organization Type
- Forecast by End-Use Org Type (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- Europe Totals by End-Use Org (Rolled-Up; Rounded)
- Commercial Implications (Europe)
Europe - Market by AI Technology
- Forecast by Tumor Site (USD Mill, 2023-32)
- Headlines (Europe - AI Technology)
- Where the Growth Comes From (2023->2032 Lift)
- Commercial Implications
Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- Europe Pathway Stage Totals
- Commercial Implications

SECTION 9 - GERMANY

Germany - Market Overview and Analysis

Headlines
What's Driving Germany (Why This Curve Is Steep)
"So What" - GTM & Packaging for Germany
Germany - At a Glance
- Key Numbers
- 2032 Mix Snapshot (steady state)
- Where the Dollars Come From ('23->'32 Lift)
- Three Takeaways
Buyer & Hosting Posture (Germany)
Incidence & Screening - Context Signals
What To Watch (Germany)

Germany - Market Estimates & Forecasts

Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Germany, Modality)
- Who Contributes the Growth
- Signals to Watch (Germany-Specific)
- What This Means (Commercial Playbook)
- Risks & Watch-outs
Germany - Market Size by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Germany, Clinical Applications)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Competitive Lens (Indicative)
- Signals to Watch (Germany)
- Risks & Watch-outs
Germany - Market by Tumor Site
- Highlights
- Forecast by Tumor Site (USD Mill, 2023-32)
- What's Shifting
- What This Means (Commercial Playbook)
- Market Math & Diffusion (Germany, Tumor Site)
Germany - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (Germany, Revenue Streams)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Packaging & Monetization Guardrails (Germany)
- Signals to Watch
- Risks & Watch-outs
Germany - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting
- What This Means (Commercial Playbook)
- Market-Math & Diffusion (Germany, End-Use Orgs)
Germany - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (Germany, AI Technology)
- What This Means (Commercial Playbook)
Germany - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Germany, Pathway Stages)
- What This Means (Commercial Playbook)
- Signals to Watch (Germany)
- Risks & Watch-outs

SECTION 10 - FRANCE

Market Overview & Dynamics

Headline Math
What's Driving France
France - At a Glance
- Key Numbers
- 2032 Mix Snapshot
- Where the Dollars Come From ('23->'32 Lift)
- Three Takeaways
Buyer & Hosting Posture (What RFPs Expect)
Incidence & Screening - Context Signals (France)
Policy, Reimbursement & Data-Residency (France-specific)
Provider Landscape Snapshot (Route-to-market)
- Anchor Systems & Networks
- Local AI Ecosystem Touchpoints
Packaging & Pricing Realities (France)
- Packaging Snapshot
Evidence & Regulatory Notes
Competitive Lens (Indicative, Oncology-Relevant in FR)
"So What" for France (GTM)

France - Market Estimates & Forecasts

France - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (France, Modality)
- ho Contributes the Growth
- What This Means (Commercial Playbook)
- Competitive Lens (Indicative Clusters)
- Signals to Watch (France-specific)
- Risks & Watch-outs
France - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (France, Clinical Applications)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Competitive Lens (indicative clusters)
- Signals to Watch (France)
- Risks & Watch-outs
France - Market by Tumor Site (2023-32)
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (France, Tumor Site)
- What This Means (Commercial Playbook)
- Signals to Watch
- Risks & Watch-outs
France - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (France, Revenue Streams)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Signals to Watch
- Risks & Watch-outs
France - Market by End-Use Organization Type
- Forecast by End-Use Organization Type
- Highlights
- What's Shifting
- What This Means (Commercial Playbook)
- Market-Math & Diffusion (France, End-Use Orgs)
France - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (France, AI Technology)
- Commercial Playbook (France)
France - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- What This Means (Commercial Playbook)
- Market-Math & Diffusion (France, Pathway Stages)

SECTION 11 - UNITED KINGDOM

UK - Market Overview & Dynamics

Headline Math
What's Driving the UK
- Demand & Supply Fundamentals
- Screening Rails Moving Upstream
- Adoption Enablers
So What (Commercial Playbook)
United Kingdom - At a Glance
- Key Numbers (2023->2032)
- Three Takeaways
- Buyer & Hosting Posture (UK-specific)
- GTM Cue
Incidence & Screening - Quick Context
Policy, Reimbursement & Governance Signals (UK-Specific)
Provider Landscape Snapshot (Indicative, GTM-relevant)
Packaging & Pricing Realities (UK)
Evidence & Regulatory Notes (what buyers will ask)
Signals to Watch ('25-'28)
Competitive Lens (indicative, UK-relevant clusters)

UK - Market Estimates & Forecasts

UK - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (UK, Modality)
- Who Contributes the Growth
- What This Means (Commercial Playbook)
- Signals to Watch (Execution)
- Risks & Watch-outs
UK - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (UK, Clinical Applications)
- Commercial Playbook
UK - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (UK, Tumor Site)
UK - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (UK, Revenue Streams)
- Commercial Playbook (UK)
UK - Market by End-Use Organization Type
Forecast by End-Use Org Type (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (UK, End-Use Orgs)
UK - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (UK, AI Technology)
UK - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (UK, Pathway Stage)

SECTION 12 - ITALY

Italy - Market Overview and Dynamics

Italy - Headline Math (2023->2032)
What's Driving Italy (why the curve is steep)
"So What" - Commercial Playbook (how to win)
Italy - At a Glance
- Key Numbers
- Three Takeaways
- Where the Growth Comes From (Dollar Lift 2023->2032)
- Buyer & Hosting Posture (Italy)
- Packaging & Pricing Cues
- Risks & Watch-outs
- What to Do Next (Italy)
Incidence & Screening - Context Signals (Why Oncology AI Is a Priority)
Policy, Reimbursement & Governance (what can accelerate/slow deals)
Provider Landscape Snapshot (Indicative GTM Targets)
Packaging & Pricing Realities (Italy-specific)
Evidence & Regulatory Notes
Signals to Watch (Next 12-24 months)

Italy - Market Estimates & Forecasts

Italy - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market-Math & Diffusion (Italy, Modality)
- Commercial Playbook (Italy)
- Risks & Watch-outs
Italy - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Italy, Clinical Applications)
Italy - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Italy, Tumor Site)
- Commercial Playbook (Tumor-site lens)
Italy - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Italy, Revenue Streams)
Italy - Market by End-Use Organization Type (2023-32)
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting (So-What)
- Market Math & Diffusion (Italy, End-Use Orgs)
Italy - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (Italy, AI Technology)
Italy - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting (So-What)
- Market Math & Diffusion (Italy, Pathway Stage)

SECTION 13 - REST OF EUROPE

Market Overview and Analysis

Headline Math (ROE)
Regional Clusters & Indicative Split
Rest of Europe (ROE) - At a Glance
- Key Numbers (2023->2032)
- Three Takeaways
- Buyer & Hosting Posture (ROE)
- GTM Cue
What's Driving Each Cluster
- Spain
- BENELUX
- Nordics
- Eastern Europe
Buyer Archetypes & Hosting Posture (by Cluster)
Modality & Pathway Tilt
Packaging & Pricing Guidance (ROE)
Channel Strategy by Cluster
"So What" for Execution
Signals to Watch
Risks & Watch-outs

ROE - Market Estimates & Forecasts

ROE - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Commercial Playbook
- Market Math & Diffusion (ROE, Modality)
Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (ROE, Clinical Application)
ROE - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Commercial Playbook
- Market-Math & Diffusion (ROE, Tumor Site)
ROE - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Commercial Playbook
- Market-Math & Diffusion (ROE, Revenue Stream)
ROE - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Commercial Playbook
- Market-Math & Diffusion (ROE, End-Use Orgs)
Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Commercial Playbook
- Market-Math & Diffusion (ROE, AI Technology)
Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Commercial Playbook
- Market-Math & Diffusion (ROE, Pathway Stage)

SECTION 14 - ASIA-PACIFIC (APAC)

APAC Market Overview and Dynamics

Headlines
What's Driving the Step-Up (Pan-Regional)
Market Structure & Mix (What the Numbers Imply)
Regulatory & Reimbursement Snapshot (Operator's View)
Data Governance (Deployment Constraint & Design Choice)
State Of Market Evolution (2025-2029 -> 2030-2032)
Commercial Implications & Plays
Risks & Watch-Outs (And How to Mitigate)
What Good Looks Like (Operating Blueprint)

APAC - Market Estimates & Forecasts

APAC - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Headlines
- What's Driving Growth (Beyond the Spreadsheets)
- Modality Math (APAC Roll-Up; Rounded)
- Where the Dollars Arise (Illustrative 2032 Splits by Modality)
- Regulatory & Market-Access Cues to Watch
- Commercial Implications
APAC - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- APAC Totals by Clinical Application (Rolled-Up; Rounded)
- Who Drives Each Application? (2032 Revenue Split Within Application)
- Commercial Implications
APAC - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- Who Leads by Country/Site (2032)
- Commercial Implications
APAC - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Headlines
- Where the Dollar-Lift Comes From (2023->2032)
- Country Composition
- Commercial Cues
APAC - Market by End-Use Organization Type
- Forecast by End-Use Org Type (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- Source: Marketstrat Estimates & Forecast Model
- Who Buys Which Category (2032 Split Inside Each End-Use)
- Commercial Implications
- APAC Totals by End-Use Org (Rolled-Up; Rounded)
APAC - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- APAC Totals by AI Technology (Rolled-Up; Rounded)
- Commercial Implications
APAC - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Headlines
- Regional Synthesis
- Country / Sub-Region Pattern is Strikingly Uniform
- Market Math (Rounded, APAC Totals)
- Commercial Implications

SECTION 15 - CHINA

Market Overview and Analysis

Headline Math (China)
China - At a Glance (Key Numbers, 2023->2032)
What's Driving China
- Demand & Supply Fundamentals
- Screening Rails (Moving Upstream)
- Adoption Enablers
Buyer & Hosting Posture (China-Specific)
Commercial Playbook - How to Win
Key Takeaways (China)
Incidence & Screening - Quick Context (for planning; directional)
Provider Landscape Snapshot (indicative, GTM-relevant)
Packaging & Pricing Realities (China)
Signals to Watch ('25-'28)

China - Market Estimates & Forecasts

China - Market by Modality (2023-32)
- Forecast by Modality (USD Mill, 2023-32)
- Highlights (2023->2032)
- What's Shifting (Local Market Mechanics)
- Pricing & Packaging Posture (by Modality)
- Who Drives the Growth
- Competitive Lens
- Signals to Watch
- Risks
- Actions (90-day Playbook)
- Market Math & Diffusion (China, Modality)
China - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting (Local Mechanics)
- Market Math & Diffusion (China, Clinical Application)
- Who Drives the Growth
- Pricing & Packaging (by Application)
- Competitive Lens
- Signals to Watch
- Risks
- Actions (90-day Playbook)
China - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (China, Tumor Site)
- Who Drives the Growth
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Actions - 90-Day Playbook
China - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (China, Revenue Stream)
- Who Drives the Growth
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Actions - 90-Day Playbook
China - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Market Math & Diffusion (China, End-Use Orgs)
- Who Drives the Growth
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Risks
- Actions - 90-Day Playbook
China - Market by AI Technology (2023-32)
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (China, AI Technology)
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Risks
- Actions - 90-Day Playbook
China - Market by Pathway Stage (2023-32)
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (China, Pathway Stage)
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Risks
- Actions - 90-Day Playbook

SECTION 16 - JAPAN

Market Overview and Analysis

Headline Math
Japan - At a Glance
What's Driving Japan
- Demand & Supply Fundamentals
- Screening Rails (Upstream Engines)
- Adoption Enablers
Buyer & Hosting Posture (Japan)
Commercial Playbook - How to Win
Key Takeaways (Japan)
Incidence & Screening - Quick Context (Planning Cues)
- Signals to Watch ('25-'28)
- Risks

Market Estimates & Forecasts

Japan - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Pricing & Packaging
- Market Math & Diffusion (Japan, Modality)
- Competitive Lens
- Signals to Watch
- Risks
- Actions (90-day playbook)
Japan - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (Japan, Clinical Application)
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Actions (90-day Playbook)
Japan - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (Japan, Tumor Site)
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Risks
- Actions (90-day Playbook)
Japan - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (Japan, Revenue Stream)
- Pricing & Packaging
- Actions (90-day Playbook)
Japan - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (Japan, End-Use Orgs)
- Pricing & Packaging
- Competitive Lens
- Signals to Watch
- Actions (90-day Playbook)
Japan - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (Japan, AI Technology)
- Pricing & Packaging
- Actions (90-day Playbook)
Japan - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (Japan, Pathway Stage)
- Pricing & Packaging
- Actions (90-day Playbook)

SECTION 17 - INDIA

Market Overview & Dynamics

Headline Math (India, 2023->2032)
What's Driving India
- Demand & Supply Fundamentals
- Adoption Enablers & Guardrails
- Buyer & Hosting Posture (India-specific)
- Commercial Playbook (How to Win)
- India - At a Glance (Key Numbers, 2023->2032)
- Three Takeaways
- Incidence & Screening - Quick Context (for GTM framing)
- Competitive Lens (indicative, India-relevant Clusters)
- Packaging & Pricing Realities (India)

Market Estimates & Forecasts

India - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's shifting (India-specific)
- Who Drives the Growth
- Market Math & Diffusion (India, Modality)
- Pricing & Packaging (to win in India)
- Competitive Lens
- Signals to Watch ('25-'28)
- Risks
- 90-Day Actions (Playbook)
India - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting (India-specific)
- Who Drives the Growth
- Market Math & Diffusion (India, Clinical Application)
- Pricing & Packaging (to win in India)
- Signals to watch ('25-'28)
- Risks
- 90-day Playbook
India - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting (India-specific)
- Who Drives the Growth
- Market Math & Diffusion (India, Clinical Application)
- Pricing & Packaging (to win in India)
- Signals to watch ('25-'28)
- Risks
- 90-day Playbook
- Incidence & Screening - Quick Context (India)
- Estimated New Cases (2022)
- Programmatic Screening Rails
India - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting (India-specific)
- Who Drives the Growth
- Market Math & Diffusion
- Pricing & packaging (to win in India)
- Signals to watch ('25-'28)
- Risks
- 90-day Playbook
India - Market by End-Use Organization Type
- Forecast by End-Use Org Type (USD Mill, 2023-32)
- Highlights
- What's shifting (India-specific)
- Who Drives the Growth
- Market Math & Diffusion (India, End-Use Orgs)
- Pricing & Packaging (to win in India)
- Signals to Watch ('25-'28)
- 90-day Playbook
India - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting (India-Specific)
- Who Drives the Growth
- Market Math & Diffusion (India, AI Technology)
- Pricing & Packaging (to win in India)
- Signals to watch ('25-'28)
- 90-day Playbook
India - Market by Pathway Stage - Japan
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting (India-specific)
- Who Drives the Growth
- Market Math & Diffusion (India, Pathway Stage)
- Pricing & packaging (to win in India)
- Signals to watch ('25-'28)
- 90-day Playbook

SECTION 18 - REST OF ASIA-PACIFIC (ROAPAC)

Market Overview and Analysis

Headline Math (ROAPAC)
ROAPAC Clusters (Definitions + Countries)
What's Driving ROAPAC
- Demand & Supply Fundamentals
- Adoption Enablers
Commercial Playbook (How to Win)
Pricing & Packaging Truths
Buyer & Hosting Posture (by Cluster)
Incidence & Screening - Quick Context Signals
ROAPAC - At-a-Glance (Key Numbers, 2023->2032)
Three Takeaways
Packaging & Pricing Realities
Evidence, Regulatory & Governance Notes
Signals to Watch ('25-'28)
Competitive Lens (Indicative Clusters)

Market Estimates & Forecasts

ROAPAC - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting (by Cluster)
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (ROAPAC, Modality)
- So-What (Pricing & Packaging)
- Competitive Lens (Indicative Clusters)
- Signals to Watch ('25-'28)
- Risks
ROAPAC - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Highlights
- What's Shifting (by Cluster)
- Who Drives the Growth
- Market Math & Diffusion (ROAPAC, Clinical Application)
- So-What (Pricing/Packaging)
- Signals to Watch ('25-'28)
- Risks
ROAPAC - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting (by Cluster)
- Market Math & Diffusion (ROAPAC, Tumor Site)
- Pricing/Packaging
- Signals to Watch ('25-'28)
- Risks
- 90-day Playbook
ROAPAC - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting (by Cluster)
- Who Drives the Growth
- Market Math & Diffusion (ROAPAC, Revenue Stream)
- So-What (Pricing/Packaging)
- Signals to Watch ('25-'28)
- Risks
- 90-day Playbook
ROAPAC - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting (by Cluster)
- Who Drives the Growth
- Market Math & Diffusion (ROAPAC, End-Use Org)
- Pricing & Packaging (to win)
- Signals to watch ('25-'28)
- Risks
- 90-day Playbook
ROAPAC - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Market Math & Diffusion (ROAPAC, AI Technology)
- Who Drives the Growth ('23->'32)
- What's Shifting (by Cluster)
- Pricing & Packaging (to win)
- Signals to watch ('25-'28)
- Risks
- 90-day Playbook
ROAPAC - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting (by Cluster)
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (ROAPAC, Pathway Stage)
- Pricing & Packaging (to win)
- Signals to Watch ('25-'28)
- Risks
- 90-day Playbook

SECTION 19 - LATIN AMERICA (LATAM)

Market Overview and Dynamics

Headline Math
What's Driving LATAM (Demand & Supply Fundamentals)
Cluster Lens (Who Buys, How to Win)
Buyer & Hosting Posture
Incidence & Screening - Quick Context (Operational Impact)
Packaging & Pricing Realities
Evidence & Regulatory Notes (What Buyers will Ask)
Competitive Lens (Indicative, LATAM-relevant Clusters)
LATAM - At-a-Glance (Key Numbers, 2023->2032)
Three Takeaways
90-Day Commercial Playbook (Action)

Market Estimates & Forecasts

LATAM - Market by Modality
- Forecast by Modality (USD Mill, 2023-32)
- Clusters (Definitions & GTM Posture)
- Highlights
- What's Shifting (by Cluster)
- Who Drives the Growth
- Market Math & Diffusion (LATAM, Modality)
- Pricing & Packaging (To Win)
- Competitive Lens (Indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-day Playbook
LATAM - Market by Clinical Application
- Forecast by Clinical Application (USD Mill, 2023-32)
- Clusters (Definitions & GTM Posture)
- Highlights
- Who Drives the Growth ('23->'32 Contribution)
- Market Math & Diffusion (LATAM, Clinical Application)
- Pricing & Packaging (to win)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
LATAM - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Clusters (How to Interpret The Tumor Mix)
- Highlights
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (LATAM, Tumor Site)
- Pricing & Packaging (to Win)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
LATAM - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Clusters (Definitions & GTM Posture)
- Highlights
- Who Drives the Growth ('23->'32 Contribution)
- Market Math & Diffusion (LATAM, Revenue Stream)
- Pricing & Packaging (to win)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
LATAM - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Clusters (Operating Reality & GTM)
- Highlights
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (LATAM, End-Use Org)
- Pricing & Packaging (to win)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
LATAM - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Clusters (Operating Reality & GTM)
- Highlights
- Who Drives the Growth ('23->'32 Contribution)
- Market Math & Diffusion (LATAM, AI Technology)
- Pricing & Packaging (to win)
- Competitive Lens (Indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
LATAM - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting (mix)
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (LATAM, Pathway Stage)
- Pricing & Packaging (to win)
- Cluster Lens (Practical GTM)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook

SECTION 20 - MIDDLE EAST & AFRICA (MEA)

Market Overview and Dynamics

Headline Math
What's Driving MEA (Demand & Supply Fundamentals)
- Disease & Activity
- Capacity & Workforce Reality
- Screening Rails (High-Signal)
- Adoption Enablers
Commercial Playbook by Custer (How To Win)
MEA - At a Glance
Buyer & Hosting Posture (What Procurement asks for)
Incidence & Screening - Quick Context Cues (for GTM Planning)
Packaging & Pricing Realities
Evidence & Regulatory Notes
Signals to Watch ('25-'28)
Three Takeaways
MEA - At-a-Glance Card

Market Estimates & Forecasts

Market by Modality (2023-32)
- Forecast by Modality (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth
- Market Math & Diffusion (MEA, Modality)
- Pricing & Packaging - Actionable Posture by Cluster
- Competitive Lens (Indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-Day GTM Playbook
Market by Clinical Application
- Forecast by Clinical Application (USD Mil, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (MEA, Clinical Application)
- So-What (Pricing/Packaging)
- Competitive Lens (Indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
MEA - Market by Tumor Site
- Forecast by Tumor Site (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (MEA, Tumor Site)
- Pricing & Packaging (to win)
- Incidence & Screening - Quick Context (operational cues)
- Competitive Lens (Indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
MEA - Market by Revenue Stream
- Forecast by Revenue Stream (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (MEA, Revenue Stream)
- Pricing & Packaging (how to win)
- Competitive Lens (indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
MEA - Market by End-Use Organization Type
- Forecast by End-Use Organization Type (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (MEA, End-Use Org Type)
- Pricing & Packaging (how to win)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
MEA - Market by AI Technology
- Forecast by AI Technology (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (MEA, AI Technology)
- Pricing & Packaging (how to win)
- Competitive Lens (indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook
MEA - Market by Pathway Stage
- Forecast by Pathway Stage (USD Mill, 2023-32)
- Highlights
- What's Shifting
- Who Drives the Growth ('23->'32)
- Market Math & Diffusion (MEA, Pathway Stage)
- Pricing & Packaging (how to win)
- Competitive Lens (indicative)
- Signals to Watch ('25-'28)
- Risks
- 90-Day Playbook

Product Code: MINTH-M01119

List of Tables

Table 1: World Market for AI in Oncology Imaging by Region (2023-2032, USD Million)
Table 2: World Market for Oncology Imaging AI by Country x End-Use Org (2023)
Table 3: World Market for Oncology Imaging AI by Country x End-Use Org (2032)
Table 4: World Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 5: World Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 6: World Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 7: World Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 8: World Market for Oncology Imaging AI by End-Use Org (USD Mill, 2023-32)
Table 9: World Market for Oncology Imaging AI by Technology (USD Mill, 2023-32)
Table 10: World Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 11: World Market for Oncology Imaging AI by Region x Modality (USD Mill, 2023)
Table 12: World Market for Oncology Imaging AI by Region x Modality (USD Mill, 2032)
Table 13: World Market for Oncology Imaging AI by Region x Revenue Stream (USD Mill, 2023)
Table 14: World Market for Oncology Imaging AI by Region x Revenue Stream (USD Mill, 2032)
Table 15: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2023)
Table 16: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2032)
Table 17: World Market for Oncology Imaging AI by Tumor Site x Modality (USD Mill, 2023)
Table 18: World Market for Oncology Imaging AI by Tumor Site x Modality (USD Mill, 2032)
Table 19: World Market for Oncology Imaging AI by Tumor Site x Clinical Application (USD Mill, 2023)
Table 20: World Market for Oncology Imaging AI by Tumor Site x Clinical Application (USD Mill, 2032)
Table 21: World Market for Oncology Imaging AI by Tumor Site x Revenue Stream (USD Mill, 2023)
Table 22: World Market for Oncology Imaging AI by Tumor Site x Revenue Stream (USD Mill, 2032)
Table 23: World Market for Oncology Imaging AI by Modality x Revenue Stream (2023)
Table 24: World Market for Oncology Imaging AI by Modality X Revenue Stream (2032)
Table 25: World Market for Oncology Imaging AI by Clinical Application x Revenue Stream (2023)
Table 26: World Market for Oncology Imaging AI by Clinical Application x Revenue Stream (2032)
Table 27: World Market for Oncology Imaging AI - By Pathway Stage X Revenue Stream (USD Mill, 2023)
Table 28: World Market for Oncology Imaging AI - By Pathway Stage X Revenue Stream (USD Mill, 2032)
Table 29: World Market for Oncology Imaging AI - By Pathway Stage X Modality (USD Mill, 2023)
Table 30: World Market for Oncology Imaging AI - By Pathway Stage X Modality (USD Mill, 2032)
Table 31: World Market for Oncology Imaging AI by Pathway Stage x Clinical Application (USD Mill, 2023)
Table 32: World Market for Oncology Imaging AI by Pathway Stage x Clinical Application (USD Mill, 2032)
Table 33: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (USD Mill, 2023)
Table 34: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (USD Mill, 2032)
Table 35: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2023)
Table 36: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2032)
Table 37: North American Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 38: North American Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 39: North American Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 40: North American Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 41: North American Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 42: North American Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 43: North America Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 44: United States Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 45: United States Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 46: United States Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 47: United States Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 48: United States Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 49: United States Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 50: United States Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 51: Canadian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 52: Canadian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 53: Canadian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 54: Canadian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 55: Canadian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 56: Canadian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 57: Canadian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 58: European Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 59: European Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 60: European Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 61: European Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 62: European Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 63: European Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 64: European Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 65: German Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 66: German Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 67: German Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 68: German Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 69: German Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 70: German Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 71: German Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 72: French Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 73: French Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 74: French Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 75: French Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 76: French Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 77: French Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 78: French Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 79: UK Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 80: UK Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 81: UK Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 82: UK Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 83: UK Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 84: UK Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 85: UK Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 86: Italian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 87: Italian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 88: Italian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 89: Italian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 90: Italian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 91: Italian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 92: Italian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 93: Rest of European (ROE) Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 94: Rest of European (ROE) Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 95: Rest of European (ROE) Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32).
Table 96: Rest of European (ROE) Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 97: Rest of European (ROE) Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 98: Rest of European (ROE) Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 99: Rest of European (ROE) Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 100: APAC Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 101: APAC Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 102: APAC Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 103: APAC Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 104: APAC Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 105 APAC Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 106: Chinese Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 107: Chinese Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 108: Chinese Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 109: Chinese Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 110: Chinese Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 111: Chinese Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 112: Chinese Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 113: Japanese Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 114: Japanese Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 115: Japanese Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 116: Japanese Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 117: Japanese Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 118: Japanese Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 119: Japanese Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 120: Indian Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 121: Indian Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 122: Indian Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 123: Indian Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 124: Indian Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 125: Indian Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 126: Indian Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 127: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 128: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 129: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 130: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 131: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 132: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 133: Rest of Asia-Pacific (ROAPAC) Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 134: LATAM Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)
Table 135: MEA Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Table 136: MEA Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Table 137: MEA Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Table 138: MEA Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Table 139: MEA Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Table 140: MEA Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Table 141: MEA Market for Oncology Imaging AI by Pathway Stage (USD Mill, 2023-32)

List of Figures

Figure 1: World Oncology Imaging AI Market by Pathway Stage - 2023 vs 2032
Figure 2: Oncology Imaging AI - Global Drivers & Restraints
Figure 3: Oncology Imaging AI Market by Region - 2032 Revenue and 2023-2032 CAGR
Figure 4: Oncology Imaging AI Market by Modality - 2023 vs 2032
Figure 5: Oncology Imaging AI Market by Clinical Application - 2023 vs 2032
Figure 6: Oncology Imaging AI - Competitive Cluster Architecture
Figure 7: Oncology Imaging AI - Markintel Segmentation Compass (Full Taxonomy)
Figure 8: Oncology Imaging AI - Dual-Lens Forecast Build
Figure 9: Oncology Imaging AI - From Signals to Strategy
Figure 10: Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
Figure 11: Markintel ARC Grid - AI Software - Oncology Imaging AI
Figure 12: Markintel GTM Growth vs. Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
Figure 13: Upgrade & Package Ladder - AI Software - Oncology Imaging AI
Figure 14: Markintel M3 - Market Momentum Matrix (Imaging OEMs)
Figure 15: Markintel ARC Grid - Imaging OEMs - Oncology Imaging AI
Figure 16: Markintel GTM Growth vs. Maturity Matrix - Imaging OEM Vendors (Oncology Imaging AI)
Figure 17: Upgrade & Package Ladder - Imaging OEM Cluster - Oncology Imaging AI
Figure 18: Markintel M3 - Market Momentum Matrix - RT/Oncology Planning (Oncology Imaging AI)
Figure 19: Markintel ARC Grid - RT/Oncology Planning - Oncology Imaging AI
Figure 20: Markintel GTM Growth vs. Maturity Matrix - RT/Oncology Planning (Oncology Imaging AI)
Figure 21: Upgrade & Package Ladder - RT/Oncology Planning Cluster - Oncology Imaging AI
Figure 22: Markintel M3 - Market Momentum Matrix (AI Platform & Cloud Sub-segment)
Figure 23: Markintel ARC Grid - AI Platforms & Cloud - Oncology Imaging AI
Figure 24: Markintel GTM Growth vs. Maturity Matrix - AI Platforms and Cloud (Oncology Imaging AI)
Figure 25: Upgrade & Package Ladder - AI Platforms & Cloud - Oncology Imaging AI
Figure 26: Markintel M3 - Market Momentum Matrix (AI Providers & Teleradiology Sub-Segment)
Figure 27: Markintel ARC Grid - Providers & Teleradiology - Oncology Imaging AI
Figure 28: Markintel GTM Growth vs. Maturity Matrix - Providers & Teleradiology (Oncology Imaging AI)
Figure 29: Upgrade & Package Ladder - Providers & Teleradiology Cluster - Oncology Imaging AI
Figure 30: Markintel M3 - Market Momentum Matrix (Imaging-Pharma/CRO & Trials Key Sub-Segment)
Figure 31: Markintel ARC Grid - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
Figure 32: Markintel GTM Growth vs. Maturity Matrix - Imaging-Pharma / CRO & Trials (Oncology Imaging AI)
Figure 33: Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
Figure 34: Global Oncology Imaging AI - Country x End-Use Org (2032 Market Size and Index vs. Global Mix)
Figure 35: Global Oncology Imaging AI - Country x End-Use (Dollar Lift 2023 to 2032)
Figure 36: Global Oncology Imaging AI Market by Modality: 2023 vs. 2032
Figure 37: Global Oncology Imaging AI Growth Contribution by Modality: Dollar Lift 2023 to 2032
Figure 38: Global Oncology Imaging AI Market by Clinical Application: 2023 vs. 2032
Figure 39: Global Oncology Imaging AI Growth Contribution by Clinical Application: Dollar Lift 2023 to 2032
Figure 40: Global Oncology Imaging AI Growth Contribution by Tumor Site: Dollar Lift 2023 to 2032
Figure 41: Global Oncology Imaging AI Growth Contribution by Tumor Site: Dollar Lift 2023 to 2032
Figure 42: Global Oncology Imaging Growth Contribution by Revenue Stream: Dollar Lift 2023 to 2032
Figure 43: Global Oncology Imaging Market by End-Use Org: 2023 vs. 2032
Figure 44: Global Oncology Imaging Growth Contribution by End-Use Org: Dollar Lift 2023 to 2032
Figure 45: Global Oncology Imaging Market by AI Technology: 2023 vs. 2032
Figure 46: World Market for Oncology Imaging AI by Technology (USD Mill, 2023-32)
Figure 47: Global Oncology Imaging Market by Pathway Stage: 2023 vs. 2032
Figure 48: Global Oncology Imaging AI Growth Contribution by Pathway Stage: Dollar Lift 2023 to 2032
Figure 49: Global Oncology Imaging AI - Region x Modality (2032 Market Size and Index vs. Global Mix)
Figure 50: Global Oncology Imaging AI - Region x Modality (Dollar Lift 2023 vs 2032)
Figure 51: Global Oncology Imaging AI - Region x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 52: Global Oncology Imaging AI - Region x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 53: World Market for Oncology Imaging AI by Region x Clinical Application (USD Mill, 2032)
Figure 54: Global Oncology Imaging AI - Region x Clinical Application (Dollar Lift 2023 to 2032)
Figure 55: Global Oncology Imaging AI - Tumor Site x Modality (2032 Market Size and Index vs. Global Mix)
Figure 56: Global Oncology Imaging AI - Tumor Site x Modality (Dollar Lift 2023 to 2032)
Figure 57: Global Oncology Imaging AI - Tumor Site x Clinical Application (2032 Market Size and Index vs. Global Mix)
Figure 58: Global Oncology Imaging AI - Tumor Site x Clinical Application (Dollar Lift 2023 to 2032)
Figure 59: Global Oncology Imaging AI - Tumor Site x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 60: Global Oncology Imaging AI - Tumor Site x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 61: Global Oncology Imaging AI - Modality x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 62: Global Oncology Imaging AI - Modality x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 63: Global Oncology Imaging AI - Clinical Application x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 64: Global Oncology Imaging AI - Clinical Application x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 65: Global Oncology Imaging AI - Pathway Stage x Revenue Stream (2032 Market Size and Index vs. Global Mix)
Figure 66: Global Oncology Imaging AI - Pathway Stage x Revenue Stream (Dollar Lift 2023 to 2032)
Figure 67: Global Oncology Imaging AI - Pathway Stage x Modality (2032 Market Size and Index vs. Global Mix)
Figure 68: Global Oncology Imaging AI - Pathway Stage x Modality (2032 Market Size and Index vs. Global Mix)
Figure 69: Global Oncology Imaging AI - Pathway Stage x Clinical Application (2032 Market Size and Index vs. Global Mix)
Figure 70: Global Oncology Imaging AI - Pathway Stage x Clinical Application (Dollar Lift 2023 to 2032)
Figure 71: World Market for Oncology Imaging AI by Pathway Stage x End-use Org (2032 Market Size and Index vs. Global Mix)
Figure 72: Global Oncology Imaging AI - Pathway Stage x End-Use (Dollar Lift 2023 to 2032)
Figure 73: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (2032 Over/Under Mix)
Figure 74: World Market for Oncology Imaging AI by Pathway Stage x AI Technology (USD Mill, 2032)
Figure 75: North America - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 76: North America - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 77: North America - Country x Modality Dollar Lift, 2023 to 2032
Figure 78: North America - Clinical Application Dollar-Lift, (2023-2032) [US$M]
Figure 79: North America - Country x Clinical Application Dollar Lift, 2023 to 2032
Figure 80: North America - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 81: North America - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 82: North America - Country x Tumor Site Dollar Lift, 2023 to 2032
Figure 83: North America - Tumor Site vs Scale (Bubble = Dollar Lift)
Figure 84: North America - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 85: North America - Dollar Lift (from 2023 - 2032) by Revenue Stream (US vs Canada)
Figure 86: North America - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 87: North America - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 88: North America - Dollar Lift (from 2023 - 2032) by End-Use Org (US vs Canada)
Figure 89: North America - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 90: North America - Dollar Lift (from 2023 - 2032) by AI Technology (US vs Canada)
Figure 91: North America - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 92: North America - Dollar Lift (from 2023 - 2032) by Pathway Stage (US vs Canada)
Figure 93: United States - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 94: United States - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 95: United States - Modality Mix Shift (from 2023 to 2032) (Share Arrows)
Figure 96: United States - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 97: United States - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 98: United States - Clinical Application Shift (from 2023 to 2032) (Share Arrows)
Figure 99: United States - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 100: United States - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 101: United States - Tumor Site Mix Shift (from 2023 to 2032) (Share Arrows)
Figure 102: United States - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 103: United States - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 104: United States - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 105: United States - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 106: United States - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 107: United States - AI technology Growth vs Scale (Bubble = Dollar Lift)
Figure 108: United States - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 109: United States - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 110: Canada - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 111: Canada - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 112: Canada - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 113: Canada - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 114: Canada - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 115: Canada - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 116: Canada - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 117: Canada - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 118: Canada - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 119: Canada - End-Use Org Mix Shift, 2023 to 2032 (Share Arrows)
Figure 120: Canada - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 121: Canada - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 122: Canada - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 123: Canada - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 124: Canada - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 125: Canada - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 126: Europe - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 127: Europe - Dollar Lift '23-'32 by Modality (Stacked by Country)
Figure 128: Europe - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 129: Europe - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 130: Europe - Dollar Life '23-'32 by Clinical Application (Stacked by Country)
Figure 131: Europe - Clinical Application - Growth vs Scale (Bubble = Dollar Lift)
Figure 132: Europe - Tumor Sites Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 133: Europe - Dollar Life '23-'32 by Tumor Site (Stacked by Country)
Figure 134: Europe - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 135: Europe - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 136: Europe - Dollar Lift '23-'32 by Revenue Stream (Stacked by Country)
Figure 137: Europe - Dollar-Lift Contribution, End-User Orgs, 2023 to 2032 (Waterfall)
Figure 138: Europe - Dollar Lift '23-'32 by End-Use Org (Stacked by Country)
Figure 139: Europe - AI technologies Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 140: Europe - Dollar Lift '23-'32 by AI Technology (Stacked by Country)
Figure 141: Europe - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 142: Europe -Dollar Lift '23-'32 by Pathway Stage (Stacked by Country)
Figure 143: Germany - Modality Slope (Oncology Imaging AI), 2023-2032
Figure 144: Germany - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 145: Germany - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 146: Germany - Clinical Application Mix Shift, 2023 to 2032 (Share Arrows)
Figure 147: Germany - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 148: Germany - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 149: Germany - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 150: Germany - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 151: Germany - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 152: Germany - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 153: Germany - End-Use Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 154: Germany - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 155: Germany - End-Use Orgs Mix Shift, 2023 to 2032 (Share Arrows)
Figure 156: Germany - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 157: Germany - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 158: Germany - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 159: Germany - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 160: Germany - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 161: Germany - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 162: France - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 163: France - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 164: France - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 165: France - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 166: France - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 167: France - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 168: France - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 169: France - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 170: France - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 171: France - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 172: France - End-Use Orgs Mix Shift, 2023 to 2032 (Share Arrows)
Figure 173: France - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 174: France - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 175: France - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 176: France - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 177: UK - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 178: UK - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 179: UK - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 180: UK - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 181: UK - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 182: UK - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 183: UK - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 184: UK - Revenue Streams Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 185: UK - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 186:UK - End-Use Mix Shift, 2023 to 2032 (Share Arrows)
Figure 187: UK - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 188: UK - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 189: UK - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 190: UK - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 191: UK - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 192: UK - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 193: UK - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 194: Italy - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 195: Italy - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 196: Italy - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 197: Italy - Clinical Applications Growth vs Scale (Bubble = Dollar Lift)
Figure 198: Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 199: Italy - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 200: Italy - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 201: Italy - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 202: Italy - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 203: Italy - End-use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 204: Italy - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 205: Italy - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 206: Italy - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 207: Italy - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 208: Rest of Europe - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 209: Rest of Europe - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 210: Rest of Europe - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 211: Growth vs Scale (Bubble = Dollar Lift)
Figure 212: Rest of Europe - Clinical Application Mix Shift, 2023 to 2032 (Share Arrows)
Figure 213: Rest of Europe - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 214: Rest of Europe - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 215: Rest of Europe - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 216: Rest of Europe - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 217: Rest of Europe - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 218: Rest of Europe - End-Use Orgs Growth vs Scale (Bubble = Dollar Lift)
Figure 219: Rest of Europe - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 220: Rest of Europe - AI Technology Mix Shift, 2023 to 2032 (Share Arrows)
Figure 221: Rest of Europe - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 222: Rest of Europe - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 223: APAC - Modalities Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 224: APAC - Dollar Lift '23-'32 by Tumor Site (Stacked by Country)
Figure 225: APAC - Clinical Applications Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 226: APAC - Dollar Lift '23-'32 by Clinical Application (Stacked by Country)
Figure 227: APAC - Tumor Sites Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 228: APAC - Tumor Sites Dollar Lift '23-'32 by Tumor Site (Stacked by Country)
Figure 229: APAC - Revenue Streams Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 230: APAC - Revenue Streams Dollar Lift '23-'32 by Tumor Site (Stacked by Country)
Figure 231: APAC - End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 232: End-Use Orgs Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 233: APAC - AI Technologies Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 234: APAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 235: APAC - Pathway Stages Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 236: APAC - Dollar Lift '23-'32 by Pathway Stage (Stacked by Country)
Figure 237: China - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 238: China - Modality Mix Shift, 2023 to 2032 (Share Arrows)
Figure 239: China - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 240: China - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 241: China - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 242: China - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 243: China - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 244: China - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 245: China - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 246: China - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 247: China - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 248: Growth vs Scale (Bubble = Dollar Lift)
Figure 249: China - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 250: China - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 251: China - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 252: China - Pathway Stage Mix Shift, 2023 to 2032 (Share Arrows)
Figure 253: China - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 254: Japan - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 255: Japan - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 256: Japan - Clinical Application Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 257: Japan - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 258: Japan - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 259: Japan - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 260: Japan - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 261: Japan - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 262: Japan - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 263: Japan - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 264: Japan - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 265: Japan - End-Use Mix Shift, 2023 to 2032 (Share Arrows)
Figure 266: Japan - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 267: Japan - End-Use Org Mix Shift, 2023 to 2032 (Share Arrows)
Figure 268: Japan - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 269: Japan - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 270: Mix Shift, 2023 to 2032 (Share Arrows)
Figure 271: Japan - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 272: India - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 273: India - Modality Mix Shift, 2023 to 2032 (Share Arrows)
Figure 274: India - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 275: India - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 276: India - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 277: India - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 278: India - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 279: India - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 280: India - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 281: India - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 282: Growth vs Scale (Bubble = Dollar Lift)
Figure 283: India - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 284: India - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 285: India - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 286: India - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 287: India - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 288: ROAPAC - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 289: ROAPAC - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 290: ROAPAC - Clinical Application Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 291: ROAPAC - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 292: ROAPAC - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 293: ROAPAC - Tumor Site Mix Shift, 2023 to 2032 (Share Arrows)
Figure 294: ROAPAC - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 295: ROAPAC - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 296: ROAPAC - Revenue Stream Mix Shift, 2023 to 2032 (Share Arrows)
Figure 297: ROAPAC - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 298: ROAPAC - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 299: ROAPAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 300: ROAPAC - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 301: ROAPAC - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 302: ROAPAC - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)
Figure 303: LATAM Market for Oncology Imaging AI by Modality (USD Mill, 2023-32)
Figure 304: Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 305: LATAM - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 306: LATAM Market for Oncology Imaging AI by Clinical Application (USD Mill, 2023-32)
Figure 307: LATAM - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 308: LATAM - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 309: LATAM Market for Oncology Imaging AI by Tumor Site (USD Mill, 2023-32)
Figure 310: LATAM - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 311: LATAM - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 312: LATAM Market for Oncology Imaging AI by Revenue Stream (USD Mill, 2023-32)
Figure 313: LATAM - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 314: LATAM - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 315: LATAM Market for Oncology Imaging AI by End Use Org (USD Mill, 2023-32)
Figure 316: LATAM - End-Use Org Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 317: Growth vs Scale (Bubble = Dollar Lift)
Figure 318: LATAM Market for Oncology Imaging AI by AI Technology (USD Mill, 2023-32)
Figure 319: LATAM - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 320: LATAM - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 322: LATAM - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 323: Growth vs Scale (Bubble = Dollar Lift)
Figure 325: MEA - Modality Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 326: MEA - Modality Growth vs Scale (Bubble = Dollar Lift)
Figure 328: MEA - Clinical Application Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 329: MEA - Clinical Application Growth vs Scale (Bubble = Dollar Lift)
Figure 331: MEA - Tumor Site Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 332: MEA - Tumor Site Growth vs Scale (Bubble = Dollar Lift)
Figure 334: MEA - Revenue Stream Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 335: MEA - Revenue Stream Growth vs Scale (Bubble = Dollar Lift)
Figure 337: MEA - End-Use Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 338: MEA - End-Use Org Growth vs Scale (Bubble = Dollar Lift)
Figure 340: MEA - AI Technology Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 341: MEA - AI Technology Growth vs Scale (Bubble = Dollar Lift)
Figure 343: MEA - Pathway Stage Dollar-Lift Contribution, 2023 to 2032 (Waterfall)
Figure 344: MEA - Pathway Stage Growth vs Scale (Bubble = Dollar Lift)

World Market for Oncology Imaging AI

Description

Table of Contents

List of Tables

Market Snapshot

What's Covered:

Companies Covered:

Geographical Coverage:

Market Segmentation:

Key Topics Covered:

Methodology:

TABLE OF CONTENTS

SECTION 1 - EXECUTIVE SUMMARY

Why This Market Matters - The 25-Second Read

Global Growth at A Glance (2023-2032)

Where Along the Pathway the Money Is Moving

Global Market Drivers & Restraints

Regional Pulse - Who Leads, Who Accelerates

Five Strategy Headlines to Internalize

Structural Shifts by Modality, Application, Pathway, And End-Use

Competitive Architecture and Vendor Clusters

Three-Year KPI Outlook (2025-2027) & Board-Level Actions

SECTION 2 - RESEARCH METHODOLOGY

About This Report

Scope & Segmentation - What is Being Measured

Dual-Lens Architecture - How Numbers Are Built

Top-Down Market Funnel - Anchoring the Oncology Slice

Bottom-Up Attach-Rate Flow - How Oncology Revenue Actually Accrues

Evidence Confidence - How We Weight and Quality-Check Inputs

Framework Stack - Why the Numbers Are Actionable

Company Coverage, GTM Growth-Maturity & Competitive Datasets

Upgrade & Package Ladders

Cluster-Based Competitive Architecture & Market Segment Bridging

Quality Assurance, Limitations, And Scenario Handling

SECTION 3 - STRATEGIC ANALYSIS & FRAMEWORKS

AI SOFTWARE CLUSTER

IMAGING OEMs CLUSTER (ONCOLOGY ATTACH & AI SUITES)

RT / ONCOLOGY PLANNING CLUSTER (AUTO-CONTOUR, ADAPTIVE, DOSE/RESPONSE)

AI PLATFORMS & CLOUD CLUSTER (NEUTRAL PLATFORMS, ORCHESTRATION, MARKETPLACES)

PROVIDERS & TELERADIOLOGY CLUSTER (AI-ASSISTED SERVICES)

IMAGING-PHARMA / CRO & TRIALS CLUSTER (RADIOMICS, RESPONSE, THERANOSTICS)

SECTION 4 - WORLD MARKET FOR ONCOLOGY IMAGING AI

WORLD MARKET OVERVIEW

WORLD MARKET FORECAST BY REGION (2023-2032)

WORLD MARKET BY COUNTRY x END-USE ORG

WORLD MARKET BY MODALITY

WORLD MARKET BY CLINICAL APPLICATION

WORLD MARKET BY TUMOR SITE

WORLD MARKET BY REVENUE STREAM

WORLD MARKET BY END-USE ORGANIZATION TYPE

WORLD MARKET BY AI TECHNOLOGY

WORLD MARKET BY PATHWAY STAGE

REGIONAL MIX & MOMENTUM - WORLD ONCOLOGY IMAGING AI

DISEASE-DRIVEN DEMAND MAP - WORLD ONCOLOGY IMAGING AI

WORKFLOW ECONOMICS - WORLD ONCOLOGY IMAGING AI

PATHWAY STAGE ECONOMICS - WORLD ONCOLOGY IMAGING AI

SECTION 5 - NORTH AMERICA

North America - Market Overview & Dynamics

Market Analysis & Estimates + Forecasts

SECTION 6 - UNITED STATES

US Market Overview and Dynamics

US Market Estimates & Forecasts

SECTION 7 - CANADA

Canada - Market Estimates & Forecasts (Canada)

SECTION 8 - EUROPE

Market Overview and Dynamics

Market Estimates & Forecasts

SECTION 9 - GERMANY

Germany - Market Overview and Analysis

Germany - Market Estimates & Forecasts

SECTION 10 - FRANCE

Market Overview & Dynamics

France - Market Estimates & Forecasts

SECTION 11 - UNITED KINGDOM

UK - Market Overview & Dynamics

UK - Market Estimates & Forecasts

SECTION 12 - ITALY

Italy - Market Overview and Dynamics

Italy - Market Estimates & Forecasts

SECTION 13 - REST OF EUROPE